Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Korean Association for the Study of Intestinal Diseases 2022-01-01
Sarja:Intestinal Research
Aiheet:
vedolizumab
ulcerative colitis
surgical complications
crohn disease
inflammatory bowel disease
Linkit:http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Internet

http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Samankaltaisia teoksia